---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-007956"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T14:46:51.193052+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix reports 2021 revenue $5.2M, net loss $20.2M; cash $53.8M; pipeline milestones set

## Summary
- Revenue $5.2M in 2021 vs $12.6M in 2020; net loss $20.2M vs $19.3M; EPS ($8.63).
- Cash $53.8M at Dec 31, 2021; raised $46.75M in 2021; funded into Q1 2024.
- Hired Dr. Margaret Wasilewski as CMO; completed 1-for-20 reverse stock split; regained Nasdaq compliance.
- Pulmazole Phase 2b in ABPA to start Q1 2023, data mid-2024; PUR3100 Phase 1 in Australia Q3 2022.
- PUR1800 Phase 1b met safety endpoint; preclinical tox supports chronic dosing in COPD, asthma, IPF.

## SEC filing metadata
- accession: 0001493152-22-007956
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315222007956/0001493152-22-007956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315222007956/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-007956
- JSON: https://secwatch.observer/filing/0001493152-22-007956.json
- Plain text: https://secwatch.observer/filing/0001493152-22-007956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.